Roth Capital Lowers Bio-Path (BPTH) PT to $2 Amidst Pipeline Updates, Liquidity Concerns

On Tuesday, Roth Capital revised its price target for Bio-Path Holdings Inc. (OTC:BPTH) to $2 from $9, while keeping a Buy rating on the shares.

Keep Reading →